The MARIPOSA intervention was conducted as a global randomized phase 3 trial to compare the efficacy and safety of amivantamab–lazertinib combination therapy against osimertinib monotherapy in previously untreated EGFR-mutated advanced NSCLC patients. Here, EGFR is linked to non-small cell lung carcinoma.